Leadership & Pay ·
On September 10, 2026, BioMarin Pharmaceutical Inc.'s Board of Directors increased its size from ten to eleven members…
BMRNBiomarin Pharmaceutical Inc
On September 10, 2026, BioMarin Pharmaceutical Inc.'s Board of Directors increased its size from ten to eleven members and appointed Robert Plenge, M.D., Ph.D., as an independent non-employee director. Dr. Plenge was simultaneously appointed to the Science and Technology Committee. In connection with his appointment, he received restricted stock units valued at $400,000 under the Company’s 2017 Equity Incentive Plan, vesting prior to the next annual meeting. He will receive standard director fees and committee retainers as outlined in the company's proxy statement. BioMarin Pharmaceutical Inc. operates in the biotechnology industry, focusing on the discovery, development, and commercialization of therapies for rare genetic diseases.